Stockreport

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell Therapeutics Corp. - Common Shares  (BCTX) 
PDF Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cance [Read more]